Drug Sponsors

Senesco completes acquisition of Fabrus

Friday, May 23, 2014 02:34 PM

Senesco Technologies, a clinical stage biotech company specializing in cancer therapeutics, has completed its acquisition of Fabrus, a biotechnology company focused on expanding the clinical impact of antibodies by addressing drug targets resistant to traditional antibody discovery methods.

More... »

WIRB Copernicus Group

Abbott acquires CFR Pharmaceuticals, expanding Latin American presence

Monday, May 19, 2014 01:24 PM

Abbott will acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence.

More... »


AstraZeneca rejects Pfizer’s “final” acquisition offer

Monday, May 19, 2014 12:02 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Barely nine hours after Pfizer made its fourth and “final” takeover offer, raising it to $118 billion, AstraZeneca rejected it today, ending the U.S. pharma giant’s plan to create the world’s largest biopharmaceutical company.

More... »

Bayer to divest interventional device business to Boston Scientific

Friday, May 16, 2014 12:50 PM

Bayer HealthCare will sell its interventional device business to Boston Scientific. The total consideration for the transaction, including fees for transitional services, is $415 million.

More... »

Janssen Labs expands to San Francisco, adds three to @LabCentral

Thursday, May 15, 2014 01:26 PM

Janssen Labs, part of Janssen R&D, plans to open Janssen Labs @South San Francisco, a new 30,000-square-foot, standalone operation based in South San Francisco, Calif. The new location will accommodate up to 50 independent, emerging companies to be co-located with staff from Johnson & Johnson Innovation. Like the flagship Janssen Labs in San Diego, Janssen Labs @South San Francisco will include a combination of shared and private lab and office spaces and feature value-added solutions including operational support, education and business services. Janssen Labs @South San Francisco is scheduled to open at the end of the year.

More... »

Merck sells ophthalmology business to Santen for $600 million

Wednesday, May 14, 2014 01:33 PM

Santen Pharmaceutical has purchased Merck's ophthalmology products in Japan and key markets in Europe and Asia Pacific.

More... »

MabVax Therapeutics, Telik to merge

Wednesday, May 14, 2014 01:22 PM

MabVax Therapeutics, a privately held cancer immunotherapy company, and Telik, a clinical stage oncology drug development company, have agreed to merge. MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer. 

More... »

Allergan board unanimously rejects unsolicited offer from Valeant

Monday, May 12, 2014 04:08 PM

Allergan today said its board of directors has unanimously rejected the April 22 unsolicited proposal by Valeant Pharmaceuticals International. After a comprehensive review, conducted in consultation with its financial and legal advisors, the Allergan board concluded the proposal substantially undervalues Allergan, creates significant risks and uncertainties for the stockholders of Allergan and is not in the best interests of the company and its stockholders.

More... »

Shire acquires Lumena Pharmaceuticals

Monday, May 12, 2014 12:21 PM

Shire will acquire Lumena Pharmaceuticals, a biopharmaceutical company with rare disease pipeline assets, for an upfront payment of $260 million in cash, plus a payment at closing and near-term contingent milestone payments related to ongoing clinical trials.

More... »

Akorn to acquire VersaPharm for $440 million

Monday, May 12, 2014 12:17 PM

Akorn, a niche pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals, will acquire VPI Holdings, the parent company of VersaPharm, a developer and marketer of generic pharmaceuticals to niche markets within the U.S., for $440 million in cash.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 18

Ebola outbreak highlights need to improve biosafety, infrastructure to handle future health emergencies

More African American professional women open to participating in medical research

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs